BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26687834)

  • 1. Statins and survival outcomes in patients with metastatic renal cell carcinoma.
    McKay RR; Lin X; Albiges L; Fay AP; Kaymakcalan MD; Mickey SS; Ghoroghchian PP; Bhatt RS; Kaffenberger SD; Simantov R; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Jan; 52():155-62. PubMed ID: 26687834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials.
    Sorich MJ; Kichenadasse G; Rowland A; Woodman RJ; Mangoni AA
    Int J Cancer; 2016 May; 138(9):2293-9. PubMed ID: 26685869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Lalani AA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):724-732. PubMed ID: 28645482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.
    Grünwald V; McKay RR; Krajewski KM; Kalanovic D; Lin X; Perkins JJ; Simantov R; Choueiri TK
    Eur Urol; 2015 May; 67(5):952-8. PubMed ID: 25577718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
    McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
    Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma.
    Busch J; Seidel C; Erber B; Issever AS; Hinz S; Kempkensteffen C; Magheli A; Miller K; Grünwald V; Weikert S
    Eur Urol; 2013 Jul; 64(1):62-70. PubMed ID: 22999519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma.
    Haddad AQ; Jiang L; Cadeddu JA; Lotan Y; Gahan JC; Hynan LS; Gupta N; Raj GV; Sagalowsky AI; Margulis V
    Urology; 2015 Dec; 86(6):1146-52. PubMed ID: 26416007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
    Escudier B; Bellmunt J; Négrier S; Bajetta E; Melichar B; Bracarda S; Ravaud A; Golding S; Jethwa S; Sneller V
    J Clin Oncol; 2010 May; 28(13):2144-50. PubMed ID: 20368553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma.
    Alimohamed N; Lee JL; Srinivas S; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Vaishampayan UN; Tan MH; Rha SY; Donskov F; Tantravahi S; Kollmannsberger C; North S; Rini BI; Choueiri TK; Heng DY
    Clin Genitourin Cancer; 2014 Aug; 12(4):e127-31. PubMed ID: 24485801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
    Hamieh L; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Apr; 15(2):221-229. PubMed ID: 27460432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
    Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
    Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
    Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.